Cargando…

Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders

Neuroinflammatory disorders preferentially impair the higher cognitive and executive functions of the prefrontal cortex (PFC). This includes such challenging disorders as delirium, perioperative neurocognitive disorder, and the sustained cognitive deficits from “long-COVID” or traumatic brain injury...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnsten, Amy F. T., Ishizawa, Yumiko, Xie, Zhongcong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080530/ https://www.ncbi.nlm.nih.gov/pubmed/37029295 http://dx.doi.org/10.1038/s41380-023-02057-4

Ejemplares similares

Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
por: Fesharaki-Zadeh, Arman, et al.
Publicado: (2023)

Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID
por: Fesharaki Zadeh, Arman, et al.
Publicado: (2023)

Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale
por: Janssen, Rob, et al.
Publicado: (2019)

Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder
por: Arnsten, Amy FT, et al.
Publicado: (2005)

The genie in the bottle-magnified calcium signaling in dorsolateral prefrontal cortex
por: Arnsten, Amy F. T., et al.
Publicado: (2020)

Regulation of β(2)-adrenoceptors in brain glia: implications for neuroinflammatory and degenerative disorders
por: Ryan, Karen M., et al.
Publicado: (2020)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2021)

Mood Disorders, Circadian Rhythms, Melatonin and Melatonin Agonists
por: Quera Salva, M.A., et al.
Publicado: (2012)

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2022)

Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders
por: Yang, Shengtao, et al.
Publicado: (2022)

Role and rationale for the use of milnacipran in the management of fibromyalgia
por: Kranzler, Jay D, et al.
Publicado: (2010)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress
por: Hains, Avis Brennan, et al.
Publicado: (2015)

Scientific Respiratory Symposium, Paris June 2010
por: Dalglish, Gavin, et al.
Publicado: (2011)

Doing Science: managing colleagues and collaborations in scientific research
por: Hardavella, Georgia, et al.
Publicado: (2015)

Inhaled β(2)-agonists in asthma management: an evolving story
por: Silva, Diana, et al.
Publicado: (2016)

Doing science: how to get credit for your scientific work
por: Caudri, Daan, et al.
Publicado: (2015)

Neural signatures of α2-Adrenergic agonist-induced unconsciousness and awakening by antagonist
por: Ballesteros, Jesus Javier, et al.
Publicado: (2020)

β(2)‐Adrenoceptor agonist activity of higenamine
por: Hudzik, Thomas J., et al.
Publicado: (2021)

Effects of the α(1)-adrenoceptor agonist phenylephrine on SART stress-induced orthostatic hypotension in rats
por: Funakami, Yoshinori, et al.
Publicado: (2010)

Alpha-2 adrenoceptor agonists and sepsis: improved survival?
por: Quintin, Luc
Publicado: (2010)

Paradoxical bronchoconstriction caused by β(2)-adrenoceptor agonists
por: Ayed, Khadija, et al.
Publicado: (2020)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Howland, Robert H
Publicado: (2009)

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole
por: Gentile, Salvatore
Publicado: (2009)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G.W., et al.
Publicado: (2022)

Scientific Rationale for the Use of Alpha-Adrenergic Agonists and Glucocorticoids in the Therapy of Pediatric Stridor
por: Nino, Gustavo, et al.
Publicado: (2011)

Targeting the “hallmarks of aging” to slow aging and treat age-related disease: fact or fiction?
por: Keshavarz, Maryam, et al.
Publicado: (2022)

An α(2)-adrenoceptor agonist: Dexmedetomidine induces protective cardiomyocyte hypertrophy through mitochondrial-AMPK pathway
por: Weng, Xiaojian, et al.
Publicado: (2020)

Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022
por: Tan, Shing Cheng, et al.
Publicado: (2023)

Commentary by Spear, R. on “Integration of Water, Sanitation, and Hygiene for the Prevention and Control of Neglected Tropical Diseases: A Rationale for Inter-Sectoral Collaboration:” Can the Control of NTDs Profit from a Good WASH?
por: Spear, Robert C.
Publicado: (2013)

Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study
por: Stracke, Sylvia, et al.
Publicado: (2020)

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
por: Mahapatra, Manoj K., et al.
Publicado: (2022)

Structure and Function of an Irreversible Agonist-β(2) Adrenoceptor complex
por: Rosenbaum, Daniel M., et al.
Publicado: (2011)

Functional desensitization of the β(2) adrenoceptor is not dependent on agonist efficacy
por: Rosethorne, Elizabeth M, et al.
Publicado: (2015)

A Selective Pharmacophore Model for β(2)-Adrenoceptor Agonists
por: Xing, Rui-Juan, et al.
Publicado: (2009)

On the Site and Mechanism of Action of β(3)-Adrenoceptor Agonists in the Bladder
por: Andersson, Karl Erik
Publicado: (2017)

Personalized multistep cognitive behavioral therapy for obesity
por: Dalle Grave, Riccardo, et al.
Publicado: (2017)

Arrhythmias and Cognitive Function: What is the Best Practice?
por: Rusia, Akash, et al.
Publicado: (2018)

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ch1uid7iuggn99kp2p0jnj3en